Table 2.

Factors associated with success of the first major interventions for severe skin rash (n=36)

Factor	No. of patients with success (%)	p-value
Sex
Male	11/17 (64.7)	0.676
Female	11/19 (57.9)
Age (yr)
< 65	13/20 (65.0)	0.593
≥ 65	9/16 (56.3)
Type of major intervention
Systemic steroid only	7/15 (46.7)	0.384
Imatinib dose modification	9/13 (69.2)
Systemic steroid+imatinib dose modification	6/8 (75.0)
Starting dose of steroid (mg/day)
< 15	4/7 (57.1)	0.685
15-30	4/9 (44.4)
≥ 30	5/7 (71.4)
Duration of steroid starting dose (wk)
< 1	3/6 (50.0)	0.331
1-2	7/9 (77.8)
2-3	1/4 (25.0)
3-4	2/3 (66.7)
4-8	0/1 (0)
Starting dose and duration of steroid
< 15 mg/day for less than 1 week	0/1 (0)	0.573
< 15 mg/day for ≥ 1 week	4/6 (66.7)
≥ 15 mg/day for less than 1 week	1/3 (33.3)
≥ 15 mg/day for ≥ 1 week	8/13 (61.5)
Duration of steroid tapering (wk)
No tapering	6/7 (85.7)	0.173
< 1	0/1 (0)
1-2	3/4 (75.0)
2-3	1/3 (33.3)
3-4	0/1 (0)
4-8	0/2 (0)
≥ 8	3/5 (60.0)
Blood eosinophil counts at initiation of interventions (/μL)
< 500	12/13 (92.3)	0.011
≥ 500	10/21 (47.6)